Central Retinal Vein Occlusion

Overview of diagnosis and treatment of central retinal vein occlusion.

What is a Central Retinal Vein Occlusion?

The inner layers of the retina receive their blood supply from the central retinal artery. The blood returns to the heart through the central retinal vein. Both vessels enter the eye through a small opening in the middle of the optic nerve. Either because this opening shrinks or because the artery hardens or because of circulations problems, the central retinal vein can become partially or completely occluded. When a patient develops a central retinal vein occlusion (CRVO), they lose some or most of their central vision. The photograph of the retina on the right is of an eye with 20/50 visual acuity with a central retinal vein occlusion for 6 weeks. The retinal veins dilate and there are retinal hemorrhages. Patients often develop swelling of the central retina-cystoid macular edema--causing some of the vision loss. Without treatments, 25% of eyes improve, 50% stabilize, and 25% worsen.

Lucentis for Central Retinal Vein Occlusion

Monthly Lucentis therapy is also helpful in improving vision in patients with central retinal vein occlusion and macular edema. Without treatment about 15 percent of have visual improvement. With treatment about 50 percent of patients have improved vision. Long term follow-up show that at 4 years, a little over half of the patients with central retinal vein occlusion require continued treatment to maintain the visual benefit.


Eylea for Central Retinal Vein Occlusion

Monthly Eylea therapy is also helpful in improving vision in patients with central retinal vein occlusion and macular edema. Without treatment about 15 percent of have visual improvement. With treatment about 60 percent of patients have improved vision.


Central Retinal Vein Occlusion NEWS

Below are current articles from a Google News Feed on Central Retinal Vein Occlusion

This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in ...
Dove Medical Press
... frequency of vascular endothelial growth factor (VEGF) antagonists in the treatment of macular edema secondary to retinal vein occlusion (RVO) in clinical practice. Patients and methods: A multicenter retrospective study of the medical records of ...

and more »

Digital Journal

Retinal Vein Occlusion Market 2018 Highlights | By Types – Branch Retinal Artery Occlusion, Central Retinal Vein ...
Digital Journal
The Global Retinal Vein Occlusion Market is expected to grow at a CAGR of 11.2% during the forecast period 2017-2023. Glaucoma is a condition where the eye pressure causes damage to the optic nerve. The increasing number of patients with glaucoma is ...

and more »

Ozurdex® (dexamethasone 0.7mg) now available for millions of patients in China with macular edema secondary to ...
Markets Insider
DUBLIN, March 22, 2018 /PRNewswire/ -- Today, Allergan plc (NYSE:AGN) announces the launch of Ozurdex® (dexamethasone intravitreal implant 0.7 mg) in China for the treatment of adult patients with macular edema secondary to retinal vein occlusion (RVO ...


Retinal Vein Occlusion Market 2018 Audit | Competitive Analysis with Top Region Overview | Iconic Growth of 11.2% by ...
Industry Today (press release)
The Global Retinal Vein Occlusion Market is segmented on the basis of type, condition, diagnosis, treatment, and end user. On the basis of the type, it is segmented into branch retinal artery occlusion and central retinal vein occlusion. On the basis ...

and more »

Week Herald

Zacks Investment Research Downgrades Regeneron (NASDAQ:REGN) to Hold
Week Herald
... develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic ...
Regeneron (REGN) Stake Lowered by Envestnet Asset Management Inc.The Ledger Gazette
BidaskClub Downgrades Regeneron (REGN) to SellStockNewsTimes
Regeneron (REGN) Given Market Perform Rating at Raymond Jamesregistrarjournal.com
Enterprise Leader -Zacks -SEC.gov
all 73 news articles »

Wall Street Morning

LPL Financial LLC Has $3.64 Million Holdings in Regeneron (NASDAQ:REGN)
StockNewsTimes
LPL Financial LLC trimmed its holdings in shares of Regeneron (NASDAQ:REGN) by 13.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 9,689 shares of the ...
Raymond James Financial Reaffirms Market Perform Rating for Regeneron (NASDAQ:REGN)Macon Daily
Regeneron (REGN) Earning Somewhat Favorable Media Coverage, Report Findsregistrarjournal.com
Regeneron Pharmaceuticals, Inc. - REGN - Stock Price Today - ZacksZacks
SEC.gov
all 85 news articles »

Global Ophthalmic Suspension Market: Full in-Depth Analysis by Regional Outlook, Growth, Trend, Share, Size and ...
Digital Journal
Retinal disorder is further sub segmented into macular degeneration, branch retinal vein occlusion, central retinal vein occlusion, congenital X-linked retinoschisis and others. On the basis of end user the market is segmented into hospitals, eye ...

and more »

Weekly Register

Macquarie Group Ltd. Buys 27393 Shares of Regeneron (NASDAQ:REGN)
Macon Daily
Macquarie Group Ltd. boosted its holdings in shares of Regeneron (NASDAQ:REGN) by 102.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 54,124 shares of ...
Reviewing Kite Pharma (KITE) and Regeneron (REGN)The Ledger Gazette
Analysts Expect Regeneron (REGN) Will Announce Quarterly Sales of $1.53 Billionregistrarjournal.com
Regeneron Pharmaceuticals, Inc. - REGN - Stock Price Today - ZacksZacks
SEC.gov
all 120 news articles »

Ophthalmic Suspension Market By Current Scenario, Key Vendors, Growth Rate, Drivers, Volume & Forecast Report
Pharmaceuticals News
Retinal disorder is further sub segmented into macular degeneration, branch retinal vein occlusion, central retinal vein occlusion, congenital X-linked retinoschisis and others. On the basis of end user the market is segmented into hospitals, eye ...

and more »

Ophthalmic Suspension Market Report By Industry Trends and Forecast the Upcoming Opportunities and Threats in the ...
Pharmaceuticals News
Retinal disorder is further sub segmented into macular degeneration, branch retinal vein occlusion, central retinal vein occlusion, congenital X-linked retinoschisis and others. On the basis of end user the market is segmented into hospitals, eye ...

and more »

Global Ophthalmic Suspension Market By Industry Trends and Forecast for the Upcoming Opportunities and Threats in ...
Healthcare Trends
... retinal disorders, glaucoma, allergies and diabetic eye disease. Bacterial infection is further sub segmented into conjunctivitis, scleritis and others. Retinal disorder is further sub segmented into macular degeneration, branch retinal vein ...

and more »

Ophthalmic Suspension Market Report By Current Scenario, Key Vendors, Growth Rate, Drivers, Volume & Forecast ...
Pharmaceuticals News
Retinal disorder is further sub segmented into macular degeneration, branch retinal vein occlusion, central retinal vein occlusion, congenital X-linked retinoschisis and others. On the basis of end user the market is segmented into hospitals, eye ...


The Ledger Gazette

Reviewing Regeneron (REGN) & GlycoMimetics (NASDAQ:GLYC)
The Ledger Gazette
The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following ...

and more »

StockNewsTimes

Regeneron (REGN) Receives $449.95 Consensus Price Target from Brokerages
StockNewsTimes
Shares of Regeneron (NASDAQ:REGN) have been assigned a consensus rating of “Hold” from the thirty ratings firms that are currently covering the stock, MarketBeat reports. Three analysts have rated the stock with a sell recommendation, fifteen have ...


BZ Weekly

Allergan Announces Launch of the TrueTear® Intranasal Neurostimulation Device During 2018 ASCRS-ASOA Annual ...
PR Newswire (press release)
Allergan has launched over 125 eye care products and invested billions of dollars in new treatments for the most prevalent eye conditions including glaucoma, ocular surface disease, and retinal diseases such as diabetic macular edema and retinal vein ...
Allergan Plc - AGN - Stock Price Today - ZacksZacks
SEC FORM 4 - SEC.govSEC.gov

all 98 news articles »

StockNewsTimes

Regeneron (REGN) Position Trimmed by Gotham Asset Management LLC
StockNewsTimes
Gotham Asset Management LLC lessened its position in Regeneron (NASDAQ:REGN) by 87.8% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 4,159 shares of the biopharmaceutical company's ...
Regeneron's (REGN) “Market Perform” Rating Reaffirmed at Raymond James Financialregistrarjournal.com
Regeneron (REGN) Expected to Announce Quarterly Sales of $1.53 BillionEnterprise Leader
Regeneron Pharmaceuticals, Inc. - REGN - Stock Price Today - ZacksZacks
SEC.gov
all 108 news articles »

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) – Pipeline Insight, H1 2018
satPRnews (press release)
Report covers products from therapy areas Ophthalmology, Metabolic Disorders and Oncology which include indications Wet (Neovascular / Exudative) Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Branch Retinal Vein Occlusion, Central ...

and more »

Cystoid Macular Edema Market Value Projected to Expand by 2025
The Mobile Herald
Symptoms of cystoids macular edema are blurred or decreased central vision. The cause of CME is not completely known though it may be accompanied by various diseases such as uveitis, vein occlusion or diabetes. It is also known to occur commonly after ...


Bel Marra Health

Central retinal vein occlusion (CRVO): Types, causes, symptoms, and treatment
Bel Marra Health
Central retinal vein occlusion (CRVO) refers to a medical condition of the eye where the main vein of the retina has become blocked. Much like other organs of the human body, our eyes also require a constant supply of oxygenated blood supplied by ...


StockNewsTimes

LPL Financial LLC Sells 1442 Shares of Regeneron (NASDAQ:REGN)
StockNewsTimes
LPL Financial LLC lessened its stake in shares of Regeneron (NASDAQ:REGN) by 13.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 9,689 shares of the ...
Head-To-Head Review: Regeneron (REGN) versus Kite Pharma (KITE)Week Herald
Regeneron (REGN) Stock Rating Lowered by Zacks Investment ResearchMacon Daily
Weekly Investment Analysts' Ratings Changes for Regeneron (REGN)registrarjournal.com
SEC.gov
all 23 news articles »

StockNewsTimes

Analysts Expect Regeneron (REGN) Will Post Earnings of $4.50 Per Share
StockNewsTimes
The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following ...
TIAA CREF Investment Management LLC Decreases Position in Regeneron (NASDAQ:REGN)Macon Daily
Regeneron (NASDAQ:REGN) Lifted to Hold at BidaskClubregistrarjournal.com
OLD Mission Capital LLC Invests $420000 in Regeneron (REGN)Іnsіdеr Cаr Nеws
Alive For Football -Zacks -SEC.gov
all 109 news articles »

StockNewsTimes

Regeneron (REGN) PT Lowered to $420.00 at Credit Suisse Group
StockNewsTimes
Regeneron (NASDAQ:REGN) had its target price trimmed by Credit Suisse Group from $440.00 to $420.00 in a research report released on Tuesday. The firm currently has a buy rating on the biopharmaceutical company's stock. A number of other equities ...
Insider Selling: Regeneron (NASDAQ:REGN) Director Sells 2000 Shares of StockWeek Herald
Mackenzie Financial Corp Takes $204000 Position in Regeneron (NASDAQ:REGN)The Ledger Gazette
Regeneron Pharmaceuticals, Inc. - REGN - Stock Price Today - ZacksZacks
SEC.gov
all 125 news articles »

Week Herald

Head to Head Review: GlycoMimetics (NASDAQ:GLYC) vs. Regeneron (REGN)
Week Herald
The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following ...

and more »

MetLife Investment Advisors LLC Invests $8.96 Million in Regeneron (REGN)
Macon Daily
MetLife Investment Advisors LLC acquired a new position in Regeneron (NASDAQ:REGN) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 23,836 shares of the ...


Contrasting Regeneron (REGN) and GlycoMimetics (NASDAQ:GLYC)
registrarjournal.com
The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following ...

and more »

StockNewsTimes

Regeneron (REGN) Shares Sold by Caisse DE Depot ET Placement DU Quebec
StockNewsTimes
Caisse DE Depot ET Placement DU Quebec reduced its holdings in shares of Regeneron (NASDAQ:REGN) by 5.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The ...

and more »

Regeneron (REGN) Expected to Post Earnings of $4.49 Per Share
registrarjournal.com
... develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic ...

and more »

Head-To-Head Survey: GlycoMimetics (GLYC) versus Regeneron (REGN)
Macon Daily
The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following ...

and more »

Cardiovascular Business

Researchers confirm link between retinal vein occlusion, heart attack
Cardiovascular Business
“Similarly, the underlying mechanism of AMI involves a sclerotic artery (coronary artery), which causes thrombus formation and venous obstruction. We postulate that RVO and AMI may be associated because the changes in retinal vessels may somehow imply ...


The Lincolnian Online

Perceptive Advisors LLC Buys Shares of 20000 Regeneron (NASDAQ:REGN)
The Lincolnian Online
Regeneron logo Perceptive Advisors LLC acquired a new stake in Regeneron (NASDAQ:REGN) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 20,000 shares of the ...
Regeneron (NASDAQ:REGN) Director Joseph L. Goldstein Sells 2000 SharesMacon Daily

all 86 news articles »
» Load more